LUME-Meso Phase II/III study: nintedanib + pemetrexed/cisplatin in chemotherapy-naïve patients with malignant pleural mesothelioma
Tsao A, Vogelzang N, Nowak A, Popat S, Gaafar R, van Meerbeeck J, Nakano T, Barrueco J, Morsli N, Scagliotti G
Learn more about the science behind this poster in the papers and other materials below
Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue